Form 4: Clover Health Director Awarded RSUs, Boosts Holdings
Insider Transaction Report
Clover Health Investments Director Anna U. Loengard reported the acquisition of 79,365 restricted stock units and updated her beneficial ownership.
Summary
- Anna U. Loengard, a Director of Clover Health Investments, Corp. (CLOV), reported an acquisition of 79,365 shares of Class A Common Stock.
- These shares represent time-based restricted stock units (RSUs) awarded to Ms. Loengard.
- The RSUs will vest in full on January 6, 2027, contingent on her continued service as a director through that date.
- Ms. Loengard's direct beneficial ownership of Class A Common Stock following this transaction is 527,456 shares.
- She also reported indirect beneficial ownership of 27,600 Class A Common Stock held in a custodial IRA for her son and 29,610 Class A Common Stock held in a custodial IRA for her daughter.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as a director receiving an equity award generally indicates continued commitment and alignment with shareholder interests, which is a routine and expected event for corporate governance.
Positives
- The award of 79,365 restricted stock units to a director aligns management's interests with those of shareholders, as the value of the award is tied to the company's stock performance.
- Increased equity ownership by a director demonstrates continued commitment to the company's long-term success.
Future Outlook
The future outlook includes the vesting of 79,365 restricted stock units on January 6, 2027, provided the reporting person continues her service as a director.
Stakeholder Impact
- Shareholders: The RSU award increases the director's equity stake, potentially enhancing alignment between the director's financial interests and shareholder value creation.
Next Steps
- Anna U. Loengard's continued service as a director of Clover Health Investments, Corp. until the RSU vesting date of January 6, 2027.
Key Dates
| Date | Description |
|---|---|
| 01/06/2026 | Date of earliest transaction, representing the award of time-based restricted stock units. |
| 01/08/2026 | Date the Form 4 was signed by Peter J. Rivas as attorney-in-fact for Anna U. Loengard. |
| 01/06/2027 | Vesting date for the 79,365 restricted stock units, subject to continued service as a director. |
Keywords
Clover Health Investments, CLOV, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, director compensation, beneficial ownership, equity award
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.